The FDA has accepted BeiGene's marketing application for its BTK inhibitor zanubrutinib, granting the product Priority Review status, with Feb. 27, 2020, as the action date set by the agency. Zanubrutinib is indicated for mantle cell lymphoma patients who have undergone at least one previous line of therapy.
FDA grants accelerated review for BeiGene's mantle cell lymphoma drug
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.